| Prev Close | 6.44 |
| Open | 6.42 |
| Day Low/High | 6.42 / 6.48 |
| 52 Wk Low/High | 4.10 / 6.99 |
| Volume | 2.96M |
| Avg Volume | 6.99M |
| Exchange | NYSE |
| Shares Outstanding | 16.04B |
| Market Cap | 103.62B |
| EPS | 0.40 |
| Div & Yield | 0.28 (4.30%) |
Latest News
Renewed Speculation of ECB Tightening Boosts the Euro
Euro currency gains could slow ECB tightening speculation
European Banks Stocks Rebound as Investors Put Risk Bank Into Play
Euro currency gains could slow ECB tightening speculation
Softbank Just Spent Billions of Dollars in Only Four Weeks
Thursday's mega-investment in Indian e-commerce company Flipkart is just the latest example of SoftBank's breakneck tech investment pace.
European Bank Earnings Beat Expectations, with BNP and Credit Suisse Providing the Highlights
From Spain to Switzerland the numbers were good
Stocks to Watch if U.K. House Prices Do Crash
Investors should keep a close eye on homebuilders, REITs and so-called challenger banks.
Santander Bank Contributes Nearly $2.9 Million To 109 Non-Profit Organizations
Nearly 50% of funding supports affordable housing and financial education programs in low- and moderate-income communities
Nasdaq Set for Record Close While Dow Tumbles on Financials Drop
Goldman Sachs, UnitedHealth lead Dow lower.
Goldman Sachs, UnitedHealth Drag the Dow to Triple-Digit Loss
Goldman Sachs, UnitedHealth lead Dow lower.
Sanofi Pasteur Ships First Of Its U.S. Influenza Vaccine Doses For 2017-2018 Season
- Health care providers anticipating initial shipments by early August to kick off influenza immunization season -
Santander And New England Revolution Announce 2017 Santander Soccer Scholars(SM) Program
Fourth Annual Sweepstakes Honors Local Students' Dedication in Class and on the Field with New England Revolution VIP Match Day Experience
Santander Launches Ultimate Cash Back(SM) Credit Card: First Consumer Card To Offer Unlimited 1.5% Cash Back Rewards On All Purchases With No Annual Or Transaction Fees
Ultimate Cardholders Will Earn and Save with Cash Back Across All Categories with No Cap
Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase 2 Open-Label Extension Study With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
Alnylam Pharmaceuticals , Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today new positive results from the ongoing...
Investors May Still Need to Be Patient With Santander
The trend is up, but the testing of the 50-day line so much has me a little concerned.
World's Second-Largest Economy's Bad Debt Is an Investment Opportunity
Investors should check for progress on bad debts at next week's meeting of eurozone finance ministers.
Cramer: Here Is Why I Am So Excited About the Turn in Europe
I bet Italy is now on a growth path that it hasn't seen in ages.
